Wendy Haaland
Nurse Practitioner · Minot, NDNPI 1932296969
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 247 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $907, 4.1 times the $223 reported in 2021. Among nurse practitioner clinicians in ND with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 247 payments — averaging $13.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$641
- Lilly USA, LLC$639
- AbbVie$561
- Amgen$522
- Exact Sciences$131
- Takeda Pharmaceuticals U.S.A., Inc.$128
- plus $663 from 19 others
What the payments were for
- Food & beverage$3,284100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 60 | $641 |
| Lilly USA, LLC | 55 | $639 |
| AbbVie | 41 | $561 |
| Amgen | 37 | $522 |
| Exact Sciences | 8 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $128 |
| Astellas Pharma US Inc | 5 | $88 |
| Boehringer Ingelheim | 4 | $63 |
| GSK | 3 | $48 |
| E.r. Squibb & Sons, L.L.C. | 3 | $48 |
| Dexcom, Inc. | 3 | $47 |
| Edwards Lifesciences | 1 | $46 |
| Medtronic | 1 | $39 |
| Alkermes, Inc. | 2 | $37 |
| Paratek Pharmaceuticals, Inc. | 2 | $32 |
| AstraZeneca | 2 | $32 |
| Pfizer | 2 | $28 |
| Novartis | 2 | $28 |
| Itamar Medical Inc | 1 | $25 |
| Johnson & Johnson | 2 | $23 |
| Abbott | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
How this compares
$3,284 in reported general payments places this provider in the 95th percentile of 455 nurse practitioner providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 36 | $53,857 |
| MounjaroTirzepatide | 47 | $48,432 |
| TrulicityDulaglutide | 20 | $31,933 |
| JardianceEmpagliflozin | 27 | $31,710 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $23,872 |
| EliquisApixaban | 20 | $13,731 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $10,181 |
| JanuviaSitagliptin Phosphate | 11 | $7,080 |
| Arnuity ElliptaFluticasone Furoate | 13 | $5,846 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $3,506 |
| Rosuvastatin Calcium | 153 | $2,418 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 56 | $2,239 |
| Bupropion XlBupropion Hcl | 42 | $1,923 |
| Levothyroxine Sodium | 137 | $1,819 |
| Propranolol Hcl ErPropranolol Hcl | 17 | $1,566 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $639 | $80,36567 claims |
| Novo NordiskOzempic | $641 | $53,85736 claims |
| Boehringer IngelheimJardiance | $63 | $31,71027 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $48 | $29,71934 claims |
| PfizerEliquis | $28 | $13,73120 claims |
| AbbVieSynthroid | $561 | $1,54317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 455 nurse practitioner providers in North Dakota.
Other nurse practitioner in Minot
- Jenna KelschMinot$9K
- Jaclin SeebergMinot$4K
- Leah BrewsterMinot$3K
- Jennifer NaporaMinot$2K
- Janet MaxsonMinot$1K
- Emily GreensteinFargo$271K
- Sarah MatchaFargo$17K
- Jana SuderFargo$16K
- Lisa ClairmontBismarck$15K
- McKinzie NussBismarck$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.